natgillin/translations-raw huggingface dataset:
Farmakokinetiske populationsdata fra voksne og pædiatriske patienter tyder på, at patienter med stabil, moderat nyreinsufficiens (kreatininclearance 30 - < 60 ml/min), der får halv dosis, opnår en clofarabineksponering svarende til personer med normal nyrefunktion, som får standarddosis.
Population pharmacokinetic data from adult and paediatric patients suggest that patients with stable moderate renal impairment (creatinine clearance 30 – < 60 ml/min) receiving a 50% dose reduction achieve similar clofarabine exposure to those with normal renal function receiving a standard dose.
Farmakokinetiske populationsmodeller udviklet fra studier med patienter med Parkinsons sygdom viser, at de farmakokinetiske og farmakodynamiske effekter af safinamid ikke var afhængige af alder, køn, vægt, nyrefunktion og eksponering for levodopa, hvilket indikerer, at der ikke kræves dosisjustering på baggrund af disse variable.
Population PK models developed from studies in patients with Parkinson’s disease indicate that the pharmacokinetic and pharmacodynamics effects of safinamide were not dependent on age, gender, weight, renal function and exposure to levodopa, indicating that dose adjustments will not be required based on these variables.
Farmakokinetiske profiler for raske frivillige forsøgspersoner og patienter med diabetes (type 1 eller 2) viste, at absorptionen af insulin glulisin var ca. dobbelt så hurtig med en peak koncentration, der var ca. dobbelt så høj, sammenlignet med regular human insulin..
Pharmacokinetic profiles in healthy volunteers and diabetes patients (type 1 or 2) demonstrated that absorption of insulin glulisine was about twice as fast with a peak concentration approximately twice as high as compared to regular human insulin.
Farmakokinetiske resultater for total-darunavir efter administration af 800/100 mg darunavir/ritonavir en gang dagligt som del af et antiretroviralt regime i andet og tredje trimester af graviditeten og post partum
Pharmacokinetic results of total darunavir after administration of darunavir/ritonavir at 600/100 mg twice daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum
Farmakokinetiske resultater var de samme hos raske forsøgspersoner som hos hcv- inficerede forsøgspersoner.
Pharmacokinetic results were similar between healthy subjects and HCV-infected subjects.
Farmakokinetiske reultater indikerer, at halveringstiden var kortere (5,3 timer) end for voksne (7,2 timer), og tilsyneladende clearance var hurtigere (1,5 ml/min/kg) end hos voksne (0,96 ml/min/kg).
The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).
Farmakokinetiske simuleringer indikerer, at den overordnede eksponering (AUC0-) af 0,25 mg intravenøst palonosetron én gang dagligt i 3 dage i træk var sammenlignelig med en enkelt iv-dosis på 0,75 mg, selvom Cmax for 0,75 mg enkeltdosen var højere.
Pharmacokinetic simulations indicate that the overall exposure (AUC0-∞) of 0.25 mg intravenous palonosetron administered once daily for 3 consecutive days was similar to a single intravenous dose of 0.75 mg, although Cmax of the 0.75 mg single dose was higher.
Farmakokinetiske simuleringer indikerer, at den overordnede eksponering (AUC0-) af 0,25 mg intravenøst palonosetron én gang dagligt i 3 dage i træk var sammenlignelig med en enkelt iv-dosis på 0,75 mg, selvom Cmax for 0,75 mg enkeltdosen var højere.
Pharmacokinetic simulations indicate that the overall exposure (AUC0-) of 0.25 mg intravenous palonosetron administered once daily for 3 consecutive days was similar to a single intravenous dose of 0.75 mg, although Cmax of the 0.75 mg single dose was higher.
Farmakokinetiske studier indikerer, at imepitoin absorberes godt (> 92 %) efter oral administrering, og at der ikke forekommer nogen udtalt first pass-metabolisme.
Pharmacokinetic studies indicate that imepitoin is well absorbed (> 92 %) after oral administration and that no pronounced first pass effect occurs.
Farmakokinetiske studier vedrørende konjugeret østrogen/bazedoxifen blev udført hos raske post- menopausale kvinder, der var naturligt post-menopausale, eller som havde fået foretaget bilateral oophorektomi.
Pharmacokinetic studies for CE/bazedoxifene were conducted in healthy postmenopausal women who were naturally postmenopausal or who had undergone bilateral oophorectomy.
Farmakokinetiske undersøgelser viser, at mængden og påvisningsfrekvensen af kvantificerbare plasmakoncentrationer af 9-cis-retinsyre hos patienter med KS efter applikation af lægemidlet var sammenlignelige med mængden og påvisningsfrekvensen af kvantificerbare plasmakoncentrationer af naturligt forekommende 9-cis-retinsyre i blodbanen hos ubehandlede personer (se afsnit 5.2).
Pharmacokinetic studies indicate that the range and frequency of detection of quantifiable 9-cis- retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis-retinoic acid in untreated individuals (see section 5.2).
Farmakokinetiske/ Farmakodynamiske relationer
Pharmacokinetic / Pharmacodynamic relationships
Farmakokinetiske/farmakodynamiske forhold
Pharmacokinetics in special patient groups
Farmakokinetiske/farmakodynamiske forhold
Pharmacokinetics in special populations
Farmakokinetiske/farmakodynamiske forhold
Pharmocokinetic/pharmacodynamic relationship(s)
Farmakokinetiske/farmakodynamiske forhold
PK/PD relationship
Farmakokinetiske/farmakodynamiske forhold
PK/PD relationships
Farmakokinetiske/farmakodynamiske forhold:
Pharmacokinetic/pharmacodynamic relationship:
Farmakokinetiske/farmakodynamiske forhold: Ved en dosis af memantin på 20 mg pr. dag svarer CSF-niveauerne til ki-værdien (ki = hæmningsfaktor) for memantin, som er 0,5 µmol i den humane frontale cortex.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the (CSF) levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetiske/farmakodynamiske forhold: Ved en dosis af memantin på 20 mg pr. dag svarer CSF-niveauerne til ki-værdien (ki = hæmningsfaktor) for memantin, som er 0,5 µmol i den humane frontale cortex.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetiske/farmakodynamiske forhold: Ved en dosis af memantin på 20 mg pr. dag svarer CSF-niveauerne til ki-værdien (ki = hæmningsfaktor) for memantin, som er 0,5 µmol i den humane frontale cortex.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Farmakokinetiske/farmakodynamiske forhold: Ved en dosis af memantin på 20 mg pr. dag svarer CSF-niveauerne til ki-værdien (ki = hæmningsfaktor) for memantin, som er 0,5 µmol i den humane frontale cortex.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki= inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Farmakokinetiske/farmakodynamiske forhold: Ved en dosis af memantin på 20 mg pr. dag svarer CSF-niveauernetil ki-værdien (ki = hæmningsfaktor) for memantin, som er 0,5 µmol i den humane frontale cortex.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakolog isk aktive stof
Pharmaco- logically active substance
Farmakologis kaktive stof
Pharmaco- logically active substance
Farmakologisk aktiv stof(fer)
Pharmacologically active substance(s)
Farmakologisk virksomt stof
Pharmaco- logically active substance
FARMAKOLOGISKE EGENSKABER
PHARMACO LOGICAL PROPERTIES
FARMAKOLOGISKE EGENSKABER
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group:
FARMAKOLOGISKE EGENSKABER Farmakodynamiske egenskaber
PHARMACOLOGICAL PARTICULARS Pharmacodynamic properties
FARMAKOLOGISKE EGENSKABER IMMUNOLOGISKE EGENSKABER
PHARMACOLOGICAL PROPERTIES
Farmakonkinetiske data viste, at eksponeringen for teduglutid var meget lav i kaninfostre og diende rotteunger.
Pharmacokinetic data demonstrated that the teduglutide exposure of fetal rabbits and suckling rat pups was very low.
Farmakoterapeutisk gruppe (humant normalt immunglobulin): immunsera og immunglobuliner: immunglobuliner, normale humane, ATC-kode: J06BA
Pharmacotherapeutic group (human normal immunoglobulin): immune sera and immunoglobulins: immunoglobulins, normal human, ATC code: J06BA
Farmakoterapeutisk gruppe Immunologiske midler til fugle, levende bakterielle vacciner, ATCvet- kode: QI01AE03
Pharmacotherapeutic group: immunologicals for Aves, live bacterial vaccines ATCvet code: QI01AE03
Farmakoterapeutisk gruppe: Andre ektoparasitære midler til brug på huden.
Pharmacotherapeutic group: Other ectoparasiticides for topical use.
Farmakoterapeutisk gruppe: Andre immunstimulanter, ATC kode: L03AX11 Virkningsmekanisme
Pharmacotherapeutic group: Other immunostimulants, ATC code: L03AX11 Mechanism of action
Farmakoterapeutisk gruppe: angiotensin II-antagonister, ren, telmisartan ATCvet-kode: QC09CA07
Pharmacotherapeutic group: angiotensin II antagonists, plain, telmisartan ATCvet code: QC09CA07
Farmakoterapeutisk gruppe: Anthelmintika, benzimidazoler og beslægtede stoffer – fenbendazol.
Pharmacotherapeutic group: Anthelmintics, benzimidazole and related substances – fenbendazole.
Farmakoterapeutisk gruppe: antibakterica til systemisk brug, macrolider.
Pharmacotherapeutic group: antibacterials for systemic use, macrolides.
Farmakoterapeutisk gruppe: antibakterielt quinolon, ATCvet kode: QJ 01 MA
Pharmacotherapeutic group: antibacterial quinolone ATCvet code: QJ 01 MA
Farmakoterapeutisk gruppe: Antibiotika og kemoterapeutika til udvortes brug, antivirale midler, ATC- kode: D06BB10
Pharmacotherapeutic group: Antibiotics and chemotherapeutics for dermatological use, antivirals, ATC Code: D06BB10
Farmakoterapeutisk gruppe: Antidiabetika, blodglucosesænkende midler ekskl. insulin, ATC-kode: A10BG03.
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03.
Farmakoterapeutisk gruppe: Antidiabetika, blodglucosesænkende midler ekskl. insulin; ATC-kode: A10BG03.
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03.
Farmakoterapeutisk gruppe: Antiemetikum.
Pharmacotherapeutic group: Antiemetics.
Farmakoterapeutisk gruppe: Antiepileptika, andre antiepileptica, imepitoin ATCvet-kode: QN03AX90
Pharmacotherapeutic group: Antiepileptics Other antiepileptics imepitoin ATCvet code: QN03AX90
Farmakoterapeutisk gruppe: antiepileptika, øvrige antiepileptika, ATC-kode: N03AX18 Virkningsmekanisme
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX18 Mechanism of action
Farmakoterapeutisk gruppe: antiepileptikaøvrige antiepileptika, ATC-kode: N03AX18 Virkningsmekanisme
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX18 Mechanism of action
Farmakoterapeutisk gruppe: antihæmorrhagisk stof, blodkoaguleringsfaktor IX.
Pharmacotherapeutic Group: antihaemorrhagics, blood coagulation factor IX.
Farmakoterapeutisk gruppe: Antiinflammatorisk og antireumatisk lægemiddel, non-steroider (oxicam) ATCvet kode: QM01AC06
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATC vet code: QM01AC06
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, non-steroider (oxi- cam)
Pharmacotherapeutic group: Anti-inflammatory and Anti-rheumatic products, non-steroids (oxicams).
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, non-steroider (oxi- cam).
Pharmacotherapeutic group: Anti-inflammatory and Anti-rheumatic products, non-steroids (oxicams).
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, non-steroider (oxi-cam).
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams).
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, non-steroider (oxicam)
Pharmacotherapeutic group: Anti-inflammatory and Anti-rheumatic products, non-steroids (oxicams).
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, non-steroider (oxicam)
Pharmacotherapeutic Group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams).
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, Non-steroider, (oxicam),
Pharmacotherapeutic group: Anti-inflammatory and Anti-rheumatic products, Non-steroids (oxicams).
Farmakoterapeutisk gruppe: Antiinflammatoriske og antireumatiske lægemidler, non-steroider, coxiber.
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, coxibs.
Farmakoterapeutisk gruppe: Antineoplastiske midler, taxaner, ATC-kode: L01CD04 Virkningsmekanisme
Pharmacotherapeutic group: Antineoplastic agents, taxanes, ATC code: L01CD04 Mechanism of action
Farmakoterapeutisk gruppe: Antineoplastiske og immunmodulerende agens: immunostimulanser: interferoner, ATC-kode: L03AB13
Pharmacotherapeutic group: Antineoplastic and immunomodulating agents; immunostimulants; interferons ATC code: L03AB13
Farmakoterapeutisk gruppe: antineoplastiske stoffer, folsyreanaloger, ATC-kode L01BA04
Pharmacotherapeutic group: antineoplastic agent, folic acid analogues, ATC code: L01BA04
Farmakoterapeutisk gruppe: Antiobesitaspræparater, undtaget diætprodukter, perifert virkende antiobesitasmiddel, ATC-kode A08AB01.
Pharmaco-therapeutic group: antiobesity preparations, excl. diet products, peripherally acting antiobesity products, ATC code A08AB01.
Farmakoterapeutisk gruppe: Antiparasiticider, andre anthelmintica.
Pharmacotherapeutic group: antiparasitic product, other anthelmintic agents.
Farmakoterapeutisk gruppe: Antiparasitære midler, insekticider og repellenter – endektocider.
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents – endectocides.
Farmakoterapeutisk gruppe: antivirale lægemidler til systemisk brug, nukleosider og nukleotider ekskl. revers-transkriptasehæmmere, ATC-kode: J05AB04.
Pharmacotherapeutic group: antivirals for systemic use, nucleosides and nucleotides excl. reverse transcriptase inhibitors, ATC code: J05AB04.
Farmakoterapeutisk gruppe: Antivirale midler til systemisk brug, non-nucleosid revers transkriptase- hæmmere, ATC kode J05AG01.
Pharmacotherapeutic group: Antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors, ATC code J05AG01.
Farmakoterapeutisk gruppe: Antivirale midler til systemisk brug, non-nukleosid revers transkriptasehæmmere, ATC kode J 05 AG 01.
Pharmacotherapeutic group: Antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors, ATC code J05AG01.
Farmakoterapeutisk gruppe: Antivirale midler til systemisk brug, non-nukleosid reverse transkriptasehæmmere, ATC kode J 05 AG 01.
Pharmacotherapeutic group: Antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors, ATC code J05AG01.
Farmakoterapeutisk gruppe: Ektoparacitære midler til udvortes anvendelse, ATCvet kode: QP53AC54
Pharmacotherapeutic group: Ectoparasiticides for topical use, ATCvet code: QP53AC54
Farmakoterapeutisk gruppe: Ektoparacitære midler til udvortes anvendelse, indoxacarb.
Pharmacotherapeutic group: Ectoparasiticides for topical use, indoxacarb.
Farmakoterapeutisk gruppe: Ektoparasitære midler, insekticider og repellenter, andre ektoparasitære midler til topikal anvendelse, pyriproxyfen, kombinationer.
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, other ectoparasiticides for topical use, pyriproxyfen, combinations.
Farmakoterapeutisk gruppe: Ektoparasitære midler, insekticider og repellenter, permethrin- kombinationer
Pharmacotherapeutic group: Ectoparasiticides, insecticides and repellents, permethrin combinations.
Farmakoterapeutisk gruppe: Erstatningsprodukter for blod, ATCvet-kode: QB05AA90
Pharmacotherapeutic group: Blood substitutes, ATCvet code: QB05AA90.
Farmakoterapeutisk gruppe: Gonadotrophin-frigørende hormoner (GnRH), ATCvet-kode: QH01CA93.
Pharmacotherapeutic group: Gonadotrophin-releasing hormones (GnRH), ATCvet code: QH01CA93.
Farmakoterapeutisk gruppe: Gonadotropin-frigørende hormoner (GnRH), ATCvet-kode: QH01CA93.
Pharmacotherapeutic group: Gonadotropin-releasing hormones (GnRH), ATCvet code: QH01CA93.
Farmakoterapeutisk gruppe: Hæmostatika til lokalbrug, ATC-kode: B02BC30.
Pharmaco-therapeutic group: Local haemostatics, ATC code: B02BC30
Farmakoterapeutisk gruppe: Immunologica til canidae – levende virale vacciner.
Pharmacotherapeutic group: Immunologicals for canidae, live viral vaccines.
Farmakoterapeutisk gruppe: Immunologica til katte – levende bakterielle vacciner.
Pharmacotherapeutic group: Immunologicals for felidae – cat - live bacterial vaccines.
Farmakoterapeutisk gruppe: Immunologica, Inaktiverede virale vacciner ATCvet-kode: QI09AA03
Pharmacotherapeutic group: Immunologicals, Inactivated viral vaccines ATC vet code: QI09AA03
Farmakoterapeutisk gruppe: Immunologica, Inaktiverede virale vacciner ATCvet-kode: QI09AA03
Pharmacotherapeutic group: Immunologicals, Inactivated viral vaccines ATCvet code: QI09AA03
Farmakoterapeutisk gruppe: Immunologisk inaktiverede bakterielle vacciner til hunde.
Pharmacotherapeutic group: Immunologicals for Canidae, inactivated bacterial vaccines for dogs.
Farmakoterapeutisk gruppe: Immunologisk inaktiveret bakteriel vaccine til hund.
Pharmacotherapeutic group: Immunologicals for Canidae, inactivated bacterial vaccine for dogs.
Farmakoterapeutisk gruppe: Immunologisk produkt til fjerkræ, levende virusvaccine til tamfugle.
Immunologicals for Aves, live viral vaccines for domestic fowls.
Farmakoterapeutisk gruppe: Immunologisk præparat til canidae – hund – inaktiveret parasitisk vaccine.
Pharmacotherapeutic group: Immunologicals for canidae – dog – inactivated parasitic vaccine.
Farmakoterapeutisk gruppe: Immunologisk veterinærlægemiddel til hønsefugle, tamhøns, levende viral vaccine, aviær infektiøs bronkitis virus.
Pharmacotherapeutic group: Immunologicals for aves, domestic fowl, live viral vaccine, avian infectious bronchitis virus.
Farmakoterapeutisk gruppe: Immunologiske midler til canidae – inaktiverede bakterievacciner.
Pharmacotherapeutic group: Immunologicals for canidae, inactivated bacterial vaccines.
Farmakoterapeutisk gruppe: Immunologiske midler til canidae – levende og inaktiverede virus- og inaktiverede bakterievacciner.
Pharmacotherapeutic group: Immunologicals for canidae, live and inactivated viral and inactivated bacterial vaccines.
Farmakoterapeutisk gruppe: Immunologiske midler til canidae – levende virusvacciner og inaktiverede bakterievacciner.
Pharmacotherapeutic group: Immunologicals for canidae, live viral and inactivated bacterial vaccines.
Farmakoterapeutisk gruppe: Immunologiske midler til fugle, levende bakterielle vacciner – til hønsefugle.
Pharmacotherapeutic group: Immunologicals for Aves, live bacterial vaccines for domestic fowl.
Farmakoterapeutisk gruppe: Immunologiske stoffer til Canidae – hunde.
Pharmacotherapeutic group: Immunologicals for Canidae – dog.
Farmakoterapeutisk gruppe: immunsera immunglobiliner, specifikke immunglobuliner; ATC J06B B16.
Pharmacotherapeutic group: immune sera immunoglobulins, specific immunoglobulins; ATC Code: J06BB16.
Farmakoterapeutisk gruppe: immunsera immunglobuliner, specifikke immunglobuliner; ATC J06B B16.
Pharmacotherapeutic group: immune sera immunoglobulins, specific immunoglobulins; ATC Code: J06BB16
Farmakoterapeutisk gruppe: Immunstimulerende, kolonistimulerende faktorer, ATC-kode: L03AA02.
Pharmacotherapeutic group: immunostimulants, colony stimulating factors, ATC code: L03AA02.
Farmakoterapeutisk gruppe: Inaktiverede bakterievacciner til grise, erysipelothrix.
Pharmacotherapeutic group: Inactivated bacterial vaccines for pigs, erysipelothrix.
Farmakoterapeutisk gruppe: Inaktiverede virale vacciner - Bluetonguevirus.
Pharmacotherapeutic group: Inactivated viral vaccines – Bluetongue virus.
Farmakoterapeutisk gruppe: Inaktiverede virale vacciner til får, mod bluetonguevirus.
Pharmacotherapeutic group: Inactivated viral vaccines for sheep, bluetongue virus.
Farmakoterapeutisk gruppe: Inaktiverede virale vacciner-Bluetonguevirus ATCvet-kode: QI02AA08
Pharmacotherapeutic group: Inactivated viral vaccines – Bluetongue virus.
Farmakoterapeutisk gruppe: Inaktiverede virus- og bakterievacciner til svin.
Pharmacotherapeutic group: Inactivated viral and bacterial vaccines for pigs.
Farmakoterapeutisk gruppe: Inaktiveret vaccine mod porcint circovirus.
Pharmacotherapeutic group: Inactivated porcine circovirus vaccine.
Farmakoterapeutisk gruppe: Inaktiveret viral vaccine til svin.
Pharmacotherapeutic group: Swine inactivated viral vaccine.
Farmakoterapeutisk gruppe: inaktiveret viral vaccine, mund og klovsyge virus.
Pharmaceutical group: inactivated viral vaccine, foot-and-mouth disease virus.
Farmakoterapeutisk gruppe: Infektionssygdomme, systemiske midler; antimikrobielle midler til systemisk brug, quinoloner
Pharmacotherapeutic group: general anti-infectives for systemic use; antibacterials for systemic use, quinolone antibacterials.
Farmakoterapeutisk gruppe: Lev. panleucopenivirus+lev. rhinotracheitisvirus+lev. calicivirus+inakt. hos katte.
Pharmacotherapeutic group: immunologicals for Felidae, live and inactivated viral vaccines for cats.
Farmakoterapeutisk gruppe: levende Aujeszkys syge virus vaccine.
Pharmacotherapeutic group: live Aujeszky’s disease vaccine.
Farmakoterapeutisk gruppe: Lægemidler til behandling af acetonæmi, ATC vet-kode: QA1 6QA06
Pharmacotherapeutic group: Drugs for treatment of acetonemia, ATC vet code: QA16QA06
Farmakoterapeutisk gruppe: Muskuloskeletale system, antiinflammatoriske og antireumatiske lægemidler, non-steroider.
Pharmacotherapeutic group: Musculo-skeletal system,antiinflammatory and antirheumatic products, non-steroids.
Farmakoterapeutisk gruppe: Oral blodsukker sænkende lægemiddel; thiazolidinedioner ATC- kode: A10 BG 02
Pharmacotherapeutic group: oral blood glucose lowering drugs, thiazolidinediones, ATC code: A10
Farmakoterapeutisk gruppe: Oral blodsukker sænkende lægemiddel; thiazolidinedioner ATC- kode: A10 BG 02
Pharmacotherapeutic group: oral blood glucose lowering drugs, thiazolidinediones, ATC code: A10 BG 02
Farmakoterapeutisk gruppe: Otologika – kortikosteroider og antiinfektiva i kombination.
Pharmacotherapeutic group: Otologicals – Corticosteroids and anti-infectives in combination.
Farmakoterapeutisk gruppe: Parasitter, insekticider og afskrækningsmidler, makrocykliske laktoner, milbemyciner
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins.
Farmakoterapeutisk gruppe: Parasitter, insekticider og afskrækningsmidler, makrocykliske laktoner, milbemycinst
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins.
Farmakoterapeutisk gruppe: proteinkinasehæmmere, antineoplastiske stoffer, ATC-kode: L01XE12 Virkningsmekanisme og farmakodynamisk virkning
Pharmacotherapeutic Group: antineoplastic agent, protein kinase inhibitor, ATC Code: L01XE12 Mechanism of action and pharmacodynamic effects
Farmakoterapeutisk gruppe: Quinazolinon derivat, ATCvet-kode: QP51AX08
Pharmacotherapeutic group: Quinazolinone derivate, ATCvet code: QP51AX08
Farmakoterapeutisk gruppe: selektive immunhæmmende stoffer, ATC-kode: L04AA21 Virkningsmekanisme
Pharmacotherapeutic group: selective immunosuppressive agents, ATC code: L04AA21 Mechanism of action
Farmakoterapeutisk gruppe: Urogenitalsystem og kønshormoner: Systemiske midler til erektil dysfunktion, ATC kode G04BE03.
Pharmacotherapeutic group: Urologicals, drugs used in erectile dysfunction, ATC code: G04BE03.